Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
17 results
- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis
D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study
D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study
D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives
D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus
D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy
D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania
D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts
D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment
D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease
D1.402 - Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection
D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management
D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases
D1.403 - Use of ketotifen as treatment for post viral infection cough in children
D1.404 - Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections
D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts
D1.406 - The microbiota of the urogenital canal related to papillomavirus infection
Download the app
The congress at your fingertips
Available on
Download